There is provided FV derivatives that reduce blood clotting activity, by reducing thrombin generation, when compared to wild-type FV. In particular, the FV of the present invention comprises single-point and multi-point mutations, encompassed by aspartic acid 79 to glutamic acid 119. The derivatives can be used to treat patient with conditions necessitating reduced clotting activity.
申请公布号
WO2005007843(B1)
申请公布日期
2005.11.17
申请号
WO2004CA01089
申请日期
2004.07.23
申请人
CANADIAN BLOOD SERVICES;PRYZDIAL, EDWARD, L., G.;ZEIBDAWI, ABED;GRUNDY, JEAN
发明人
PRYZDIAL, EDWARD, L., G.;ZEIBDAWI, ABED;GRUNDY, JEAN